Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Talphera, Inc. logo — Focused on the development and commercialization of innovati...

Talphera, Inc.

Focused on the development and commercialization of innovative therapies for use in medically supervised settings

Founded 2005 United States San Mateo, United States 40 employees Debt Financing Total: $191.65M Biotechnology, Health Care +1

General Information

Company Name Talphera, Inc.
Founded Year 2005
Location United States San Mateo, United States
Founders / Decision Makers
Team member Team member
Employees 40
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Debt Financing
Social

BounceWatch is an independent company data service, not affiliated with Talphera, Inc.. To contact Talphera, Inc., visit talphera.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Talphera, Inc. compare?

A PDF of Talphera, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Talphera, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Talphera, Inc.

Talphera, Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of innovative therapies for use in medically supervised settings. The company's lead product candidate, Niyad, a lyophilized formulation of nafamostat, is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit and has received Breakthrough Device Designation Status from the FDA. Additionally, Talphera is developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe. Founded in 2005 and headquartered in the United States, Talphera, Inc. operates in the Biotechnology, Health Care, and Pharmaceutical industries. The company recently secured a $6.00M post-IPO equity investment on January 18, 2024, with investments from Nantahala Capital and Rosalind Advisors. The company's commitment to innovative therapies and its recent investment raise position Talphera, Inc. as a promising player in the evolving pharmaceutical landscape. For further information on the development status of Talphera's product candidates, interested parties can visit their website at www.talphera.com.

Business keywords: specialty pharmaceuticals, medical supervision, innovative therapies, commercialization, FDA Breakthrough Device Designation, pharmaceutical development, pre-filled syringes, anticoagulant, pain management, tablet formulation, NanoTab, sublingual administration, patient-controlled analgesia, drug/device combination

Funding Rounds & Investors (12)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing $8.00M -
18 Jan 2024
Post IPO Equity $6.00M 1
Nantahala Capital Management
18 Jan 2024
Post IPO Equity $10.00M -
18 Jul 2023
Post IPO Equity $7.50M -
27 Dec 2022
Post IPO Equity $14.00M -
15 Nov 2021
Post IPO Equity $27.50M -
20 Jan 2021
Post IPO Debt $25.00M 1
Oxford Finance LLC
03 Jun 2019
Post IPO Debt $40.00M 1
Hercules Capital
Hercules Capital
19 Dec 2013
Post IPO Equity $10.00M -
07 Jun 2012
Post IPO Debt $20.84M 1
Skyline Ventures
Skyline Ventures
13 Jul 2011

View All 12 Funding Rounds

Talphera, Inc. Alternatives & Competitors

View All Alternatives
Talphera, Inc. vs
AMW GmbH
AMW GmbH Germany

Controlled drug delivery for superior treatment. For patients, worldwide.

97 employees
Health Care, Medical Devices
Talphera, Inc. vs
QRxPharma
QRxPharma

Pioneering pain management with innovative products and advanced abuse prevention technologies

Post-IPO Equity
Biopharma, Biotechnology
Talphera, Inc. vs
MediciNova, Inc.
MediciNova, Inc.

Forte Bio-Pharma is a privately held specialty pharmaceutical company focused on in-licensing, devel...

Post-IPO Debt
16 employees
Biotechnology, Health Care
View all alternatives

FAQ About Talphera, Inc.

Focused on the development and commercialization of innovative therapies for use in medically supervised settings
Talphera, Inc. was founded in 2005.
Talphera, Inc. is headquartered in San Mateo, United States.
Talphera, Inc. operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on specialty pharmaceuticals, medical supervision, innovative therapies and commercialization.
Talphera, Inc. has approximately 40 employees.
Talphera, Inc. has completed 12 funding rounds, raising a total of $191.65M. The latest funding stage is Debt Financing.
Top alternatives and competitors to Talphera, Inc. include AMW GmbH, QRxPharma, MediciNova, Inc., Scilex Holding Company, Eiger BioPharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Talphera, Inc. and AMW GmbH are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Talphera, Inc., https://bouncewatch.com/company/talphera-inc, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes